https://stock.noler.com/us/stock/kite-pharma-inc https://stock.noler.com/us/stock/kite-pharma-inc/accounts-payable https://stock.noler.com/us/stock/kite-pharma-inc/accounts-payable-current-and-noncurrent https://stock.noler.com/us/stock/kite-pharma-inc/accretion-amortization-of-discounts-and-premiums-investments https://stock.noler.com/us/stock/kite-pharma-inc/accrued-income-taxes https://stock.noler.com/us/stock/kite-pharma-inc/accrued-liabilities-current https://stock.noler.com/us/stock/kite-pharma-inc/accrued-professional-fees-current https://stock.noler.com/us/stock/kite-pharma-inc/accrued-rent-current https://stock.noler.com/us/stock/kite-pharma-inc/accumulated-depreciation https://stock.noler.com/us/stock/kite-pharma-inc/acquisition-contingent-consideration-arrangements-change-in-amount-of-contingent-consideration-liability https://stock.noler.com/us/stock/kite-pharma-inc/acquisition-contingent-consideration-liability https://stock.noler.com/us/stock/kite-pharma-inc/acquisition-contingent-consideration-liability-current https://stock.noler.com/us/stock/kite-pharma-inc/acquisition-contingent-consideration-liability-noncurrent https://stock.noler.com/us/stock/kite-pharma-inc/acquisitions https://stock.noler.com/us/stock/kite-pharma-inc/additional-paid-in-capital https://stock.noler.com/us/stock/kite-pharma-inc/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/kite-pharma-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/kite-pharma-inc/amortization https://stock.noler.com/us/stock/kite-pharma-inc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/kite-pharma-inc/aoci https://stock.noler.com/us/stock/kite-pharma-inc/assets-fair-value-disclosure https://stock.noler.com/us/stock/kite-pharma-inc/available-for-sale-accumulated-gross-unrealized-gain-before-tax https://stock.noler.com/us/stock/kite-pharma-inc/available-for-sale-accumulated-gross-unrealized-loss-before-tax https://stock.noler.com/us/stock/kite-pharma-inc/available-for-sale-amortized-cost https://stock.noler.com/us/stock/kite-pharma-inc/available-for-sale-gross-realized-gain-loss-net https://stock.noler.com/us/stock/kite-pharma-inc/available-for-sale-gross-unrealized-gains https://stock.noler.com/us/stock/kite-pharma-inc/available-for-sale-gross-unrealized-loss https://stock.noler.com/us/stock/kite-pharma-inc/available-for-sale-in-unrealized-loss-positions-qualitative-disclosure-number-of-positions https://stock.noler.com/us/stock/kite-pharma-inc/available-for-sale-in-unrealized-loss-positions-qualitative-disclosure-number-of-positions-greater-than-or-equal-to-one-year https://stock.noler.com/us/stock/kite-pharma-inc/available-for-sale-securities https://stock.noler.com/us/stock/kite-pharma-inc/available-for-sale-transfers-to-trading-gains-losses-excluding-other-than-temporary-impairments https://stock.noler.com/us/stock/kite-pharma-inc/available-for-sale-unrealized-loss-position-12-months-or-longer-aggregate-losses https://stock.noler.com/us/stock/kite-pharma-inc/available-for-sale-unrealized-loss-position-fair-value https://stock.noler.com/us/stock/kite-pharma-inc/available-for-sale-unrealized-loss-position-twelve-months-or-longer-fair-value https://stock.noler.com/us/stock/kite-pharma-inc/capital-expenditures https://stock.noler.com/us/stock/kite-pharma-inc/capital-leases-balance-sheet-assets-by-major-class-net https://stock.noler.com/us/stock/kite-pharma-inc/capital-leases-future-minimum-payments-due https://stock.noler.com/us/stock/kite-pharma-inc/capital-leases-future-minimum-payments-due-current https://stock.noler.com/us/stock/kite-pharma-inc/capital-leases-future-minimum-payments-due-in-five-years https://stock.noler.com/us/stock/kite-pharma-inc/capital-leases-future-minimum-payments-due-in-four-years https://stock.noler.com/us/stock/kite-pharma-inc/capital-leases-future-minimum-payments-due-in-three-years https://stock.noler.com/us/stock/kite-pharma-inc/capital-leases-future-minimum-payments-due-in-two-years https://stock.noler.com/us/stock/kite-pharma-inc/capital-leases-future-minimum-payments-due-thereafter https://stock.noler.com/us/stock/kite-pharma-inc/capital-leases-lessee-balance-sheet-assets-by-major-class-accumulated-deprecation https://stock.noler.com/us/stock/kite-pharma-inc/cash https://stock.noler.com/us/stock/kite-pharma-inc/cash-and-equivalents https://stock.noler.com/us/stock/kite-pharma-inc/cash-and-restricted-cash-change-excluding-exchange-rate-effect https://stock.noler.com/us/stock/kite-pharma-inc/cash-flow-breakdown https://stock.noler.com/us/stock/kite-pharma-inc/change-in-unrealized-gain-loss-on-fair-value-hedging-instruments https://stock.noler.com/us/stock/kite-pharma-inc/class-of-warrant-or-right-exercise-price-of-warrants-or-rights https://stock.noler.com/us/stock/kite-pharma-inc/class-of-warrant-or-right-exercise-price-of-warrants-or-rights-1 https://stock.noler.com/us/stock/kite-pharma-inc/class-of-warrant-or-right-number-of-securities-called-by-warrants-or-rights https://stock.noler.com/us/stock/kite-pharma-inc/common-stock-capital-shares-reserved-for-future-issuance https://stock.noler.com/us/stock/kite-pharma-inc/common-stock-dividends-shares https://stock.noler.com/us/stock/kite-pharma-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/kite-pharma-inc/common-stock-value https://stock.noler.com/us/stock/kite-pharma-inc/comprehensive-income https://stock.noler.com/us/stock/kite-pharma-inc/comprehensive-income-net-of-tax-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/kite-pharma-inc/concept-stock-issued-tag-2 https://stock.noler.com/us/stock/kite-pharma-inc/conversion-of-stock-amount-issued https://stock.noler.com/us/stock/kite-pharma-inc/conversion-of-stock-shares-converted https://stock.noler.com/us/stock/kite-pharma-inc/costs-and-expenses-related-party https://stock.noler.com/us/stock/kite-pharma-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/kite-pharma-inc/current-assets https://stock.noler.com/us/stock/kite-pharma-inc/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/kite-pharma-inc/current-foreign-tax-expense-benefit https://stock.noler.com/us/stock/kite-pharma-inc/current-income-tax-expense-benefit https://stock.noler.com/us/stock/kite-pharma-inc/current-liabilities https://stock.noler.com/us/stock/kite-pharma-inc/current-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/kite-pharma-inc/debt-convertible-conversion-price https://stock.noler.com/us/stock/kite-pharma-inc/debt-issuance-costs-incurred-during-noncash-or-partial-noncash-transaction https://stock.noler.com/us/stock/kite-pharma-inc/deferred-federal-income-tax-expense-benefit https://stock.noler.com/us/stock/kite-pharma-inc/deferred-foreign-income-tax-expense-benefit https://stock.noler.com/us/stock/kite-pharma-inc/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/kite-pharma-inc/deferred-income-tax-liabilities https://stock.noler.com/us/stock/kite-pharma-inc/deferred-rent-credit-current https://stock.noler.com/us/stock/kite-pharma-inc/deferred-rent-credit-noncurrent https://stock.noler.com/us/stock/kite-pharma-inc/deferred-revenue https://stock.noler.com/us/stock/kite-pharma-inc/deferred-revenue-noncurrent https://stock.noler.com/us/stock/kite-pharma-inc/deferred-state-and-local-income-tax-expense-benefit https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-deferred-income https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-liabilities-net-noncurrent https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-net https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-net-current https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-net-noncurrent https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-property-plant-and-equipment https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-tax-credit-carryforwards https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-tax-deferred-expense-compensation-and-benefits https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-tax-deferred-expense-compensation-and-benefits-employee-compensation https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-deferred-rent https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-valuation-allowance-current https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-assets-valuation-allowance-noncurrent https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-liabilities https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-liabilities-current https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-liabilities-goodwill-and-intangible-assets https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-liabilities-goodwill-and-intangible-assets-intangible-assets https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-liabilities-gross-current https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-liabilities-gross-noncurrent https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-liabilities-noncurrent https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-liabilities-other https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-liabilities-property-plant-and-equipment https://stock.noler.com/us/stock/kite-pharma-inc/deferred-tax-liabilities-tax-deferred-income https://stock.noler.com/us/stock/kite-pharma-inc/depreciation-and-amortization-expense https://stock.noler.com/us/stock/kite-pharma-inc/development-stage-enterprise-deficit-accumulated-during-development-stage https://stock.noler.com/us/stock/kite-pharma-inc/dilutive-shares https://stock.noler.com/us/stock/kite-pharma-inc/dividends-common-stock-stock https://stock.noler.com/us/stock/kite-pharma-inc/dividends-payable-current-and-noncurrent https://stock.noler.com/us/stock/kite-pharma-inc/dividends-preferred-stock https://stock.noler.com/us/stock/kite-pharma-inc/due-to-related-parties-current https://stock.noler.com/us/stock/kite-pharma-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/kite-pharma-inc/effect-of-exchange-rate-on-cash https://stock.noler.com/us/stock/kite-pharma-inc/effective-tax-rate https://stock.noler.com/us/stock/kite-pharma-inc/employee-related-liabilities-current https://stock.noler.com/us/stock/kite-pharma-inc/equity-method-investments https://stock.noler.com/us/stock/kite-pharma-inc/fair-value-adjustment-of-warrants https://stock.noler.com/us/stock/kite-pharma-inc/fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/kite-pharma-inc/fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/kite-pharma-inc/fair-value-assumptions-weighted-average-volatility-rate https://stock.noler.com/us/stock/kite-pharma-inc/fair-value-investments-entities-that-calculate-net-asset-value-per-share-percent-equity-securities https://stock.noler.com/us/stock/kite-pharma-inc/federal-income-tax-expense-benefit https://stock.noler.com/us/stock/kite-pharma-inc/financing-cash-flow https://stock.noler.com/us/stock/kite-pharma-inc/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/kite-pharma-inc/finite-lived-intangible-assets-amortization-expense-after-year-five https://stock.noler.com/us/stock/kite-pharma-inc/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/kite-pharma-inc/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/kite-pharma-inc/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/kite-pharma-inc/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/kite-pharma-inc/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/kite-pharma-inc/finite-lived-intangible-assets-gross https://stock.noler.com/us/stock/kite-pharma-inc/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/kite-pharma-inc/foreign-income-tax-expense-benefit https://stock.noler.com/us/stock/kite-pharma-inc/form-d-corporate-securities https://stock.noler.com/us/stock/kite-pharma-inc/form-d-other https://stock.noler.com/us/stock/kite-pharma-inc/form-d-stocks https://stock.noler.com/us/stock/kite-pharma-inc/gain-loss-on-disposition-of-assets https://stock.noler.com/us/stock/kite-pharma-inc/gain-loss-on-sale-of-investments https://stock.noler.com/us/stock/kite-pharma-inc/general-and-administrative-expense https://stock.noler.com/us/stock/kite-pharma-inc/goodwill https://stock.noler.com/us/stock/kite-pharma-inc/held-to-maturity-securities-unrealized-loss-position-fair-value https://stock.noler.com/us/stock/kite-pharma-inc/income-loss-from-equity-method-investments https://stock.noler.com/us/stock/kite-pharma-inc/income-tax https://stock.noler.com/us/stock/kite-pharma-inc/income-tax-at-federal-statutory-rate https://stock.noler.com/us/stock/kite-pharma-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/kite-pharma-inc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/kite-pharma-inc/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/kite-pharma-inc/increase-decrease-in-due-to-related-parties https://stock.noler.com/us/stock/kite-pharma-inc/increase-decrease-in-other-operating-assets https://stock.noler.com/us/stock/kite-pharma-inc/increase-decrease-in-prepaid-expense https://stock.noler.com/us/stock/kite-pharma-inc/increase-decrease-in-restricted-cash-for-operating-activities https://stock.noler.com/us/stock/kite-pharma-inc/incremental-common-shares-attributable-to-call-options-and-warrants https://stock.noler.com/us/stock/kite-pharma-inc/incremental-common-shares-attributable-to-conversion-of-preferred-stock https://stock.noler.com/us/stock/kite-pharma-inc/incremental-common-shares-attributable-to-equity-unit-purchase-agreements https://stock.noler.com/us/stock/kite-pharma-inc/insider-transactions-preferred https://stock.noler.com/us/stock/kite-pharma-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/kite-pharma-inc/insider-transactions-warrants https://stock.noler.com/us/stock/kite-pharma-inc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/kite-pharma-inc/interest-expense https://stock.noler.com/us/stock/kite-pharma-inc/interest-paid https://stock.noler.com/us/stock/kite-pharma-inc/investing-cash-flow https://stock.noler.com/us/stock/kite-pharma-inc/investment-income-interest https://stock.noler.com/us/stock/kite-pharma-inc/lease-and-rental-expense https://stock.noler.com/us/stock/kite-pharma-inc/letters-of-credit-outstanding-amount https://stock.noler.com/us/stock/kite-pharma-inc/liabilities-fair-value-disclosure https://stock.noler.com/us/stock/kite-pharma-inc/license-costs https://stock.noler.com/us/stock/kite-pharma-inc/marketable-securities-current https://stock.noler.com/us/stock/kite-pharma-inc/net-cash-from-financing-activities https://stock.noler.com/us/stock/kite-pharma-inc/net-cash-from-investing-activities https://stock.noler.com/us/stock/kite-pharma-inc/net-cash-from-operating-activities https://stock.noler.com/us/stock/kite-pharma-inc/net-change-in-cash https://stock.noler.com/us/stock/kite-pharma-inc/net-income https://stock.noler.com/us/stock/kite-pharma-inc/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/kite-pharma-inc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/kite-pharma-inc/oci-foreign-currency-translation-adjustment-tax https://stock.noler.com/us/stock/kite-pharma-inc/oci-net-of-tax https://stock.noler.com/us/stock/kite-pharma-inc/oci-unrealized-holding-gain-loss-on-securities-arising-net-of-tax https://stock.noler.com/us/stock/kite-pharma-inc/oci-unrealized-holding-gain-loss-on-securities-arising-tax https://stock.noler.com/us/stock/kite-pharma-inc/operating-cash-flow https://stock.noler.com/us/stock/kite-pharma-inc/operating-expenses https://stock.noler.com/us/stock/kite-pharma-inc/operating-income https://stock.noler.com/us/stock/kite-pharma-inc/operating-lease-payments-due https://stock.noler.com/us/stock/kite-pharma-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/kite-pharma-inc/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/kite-pharma-inc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/kite-pharma-inc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/kite-pharma-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/kite-pharma-inc/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/kite-pharma-inc/other-accrued-liabilities-current https://stock.noler.com/us/stock/kite-pharma-inc/other-depreciation-and-amortization https://stock.noler.com/us/stock/kite-pharma-inc/other-income https://stock.noler.com/us/stock/kite-pharma-inc/other-noncash-income https://stock.noler.com/us/stock/kite-pharma-inc/other-noncash-income-expense https://stock.noler.com/us/stock/kite-pharma-inc/other-noncurrent-assets https://stock.noler.com/us/stock/kite-pharma-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/kite-pharma-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/kite-pharma-inc/other-significant-noncash-transaction-value-of-consideration-received https://stock.noler.com/us/stock/kite-pharma-inc/paid-in-capital-convertible-debt-with-conversion-feature https://stock.noler.com/us/stock/kite-pharma-inc/paid-in-capital-warrant-issued https://stock.noler.com/us/stock/kite-pharma-inc/payments-for-proceeds-from-tenant-allowance https://stock.noler.com/us/stock/kite-pharma-inc/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/kite-pharma-inc/payments-to-acquire-buildings https://stock.noler.com/us/stock/kite-pharma-inc/payments-to-acquire-equity-method-investments https://stock.noler.com/us/stock/kite-pharma-inc/payments-to-acquire-marketable-securities https://stock.noler.com/us/stock/kite-pharma-inc/payments-to-acquire-productive-assets https://stock.noler.com/us/stock/kite-pharma-inc/pending-claims-number https://stock.noler.com/us/stock/kite-pharma-inc/preferred-shares-facts https://stock.noler.com/us/stock/kite-pharma-inc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/kite-pharma-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/kite-pharma-inc/preferred-stock-shares-issued https://stock.noler.com/us/stock/kite-pharma-inc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/kite-pharma-inc/preferred-stock-value https://stock.noler.com/us/stock/kite-pharma-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/kite-pharma-inc/prepaid-expense-current https://stock.noler.com/us/stock/kite-pharma-inc/pretax-income https://stock.noler.com/us/stock/kite-pharma-inc/proceeds-from-convertible-debt https://stock.noler.com/us/stock/kite-pharma-inc/proceeds-from-issuance-initial-public-offering https://stock.noler.com/us/stock/kite-pharma-inc/proceeds-from-issuance-of-preferred-stock-and-preference-stock https://stock.noler.com/us/stock/kite-pharma-inc/proceeds-from-issuance-of-private-placement https://stock.noler.com/us/stock/kite-pharma-inc/proceeds-from-issuance-of-shares-under-incentive-and-share-based-compensation-plans https://stock.noler.com/us/stock/kite-pharma-inc/proceeds-from-issuance-of-shares-under-incentive-and-share-based-compensation-plans-including-stock-options https://stock.noler.com/us/stock/kite-pharma-inc/proceeds-from-issuance-of-unsecured-debt https://stock.noler.com/us/stock/kite-pharma-inc/proceeds-from-sale-and-maturity-of-marketable-securities https://stock.noler.com/us/stock/kite-pharma-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/kite-pharma-inc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/kite-pharma-inc/proceeds-from-stock-plans https://stock.noler.com/us/stock/kite-pharma-inc/professional-and-contract-services-expense https://stock.noler.com/us/stock/kite-pharma-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/kite-pharma-inc/property-plant-equipment https://stock.noler.com/us/stock/kite-pharma-inc/public-float https://stock.noler.com/us/stock/kite-pharma-inc/repayments-of-long-term-capital-lease-obligations https://stock.noler.com/us/stock/kite-pharma-inc/research-and-development https://stock.noler.com/us/stock/kite-pharma-inc/restricted-cash-and-cash-equivalents https://stock.noler.com/us/stock/kite-pharma-inc/restricted-cash-and-investments-noncurrent https://stock.noler.com/us/stock/kite-pharma-inc/retained-earnings https://stock.noler.com/us/stock/kite-pharma-inc/revenue https://stock.noler.com/us/stock/kite-pharma-inc/security-deposit https://stock.noler.com/us/stock/kite-pharma-inc/share-price https://stock.noler.com/us/stock/kite-pharma-inc/shareholders-equity https://stock.noler.com/us/stock/kite-pharma-inc/shares-authorized https://stock.noler.com/us/stock/kite-pharma-inc/shares-issued https://stock.noler.com/us/stock/kite-pharma-inc/shares-issued-shares-issued-for-services https://stock.noler.com/us/stock/kite-pharma-inc/shares-issued-shares-new-issues https://stock.noler.com/us/stock/kite-pharma-inc/shares-issued-value-issued-for-services https://stock.noler.com/us/stock/kite-pharma-inc/state-and-local-income-tax-expense-benefit https://stock.noler.com/us/stock/kite-pharma-inc/stock-award-accelerated-compensation-cost https://stock.noler.com/us/stock/kite-pharma-inc/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/kite-pharma-inc/stock-award-fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/kite-pharma-inc/stock-award-fair-value-assumptions-expected-volatility-rate-maximum https://stock.noler.com/us/stock/kite-pharma-inc/stock-award-fair-value-assumptions-expected-volatility-rate-minimum https://stock.noler.com/us/stock/kite-pharma-inc/stock-award-fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/kite-pharma-inc/stock-award-fair-value-assumptions-risk-free-interest-rate-maximum https://stock.noler.com/us/stock/kite-pharma-inc/stock-award-fair-value-assumptions-risk-free-interest-rate-minimum https://stock.noler.com/us/stock/kite-pharma-inc/stock-award-fair-value-assumptions-weighted-average-volatility-rate https://stock.noler.com/us/stock/kite-pharma-inc/stock-award-number-of-shares-authorized https://stock.noler.com/us/stock/kite-pharma-inc/stock-award-number-of-shares-available-for-grant https://stock.noler.com/us/stock/kite-pharma-inc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/kite-pharma-inc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/kite-pharma-inc/stock-based-compensation https://stock.noler.com/us/stock/kite-pharma-inc/stock-compensation-tax-benefit-realized-from-exercise-of-stock-options https://stock.noler.com/us/stock/kite-pharma-inc/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/kite-pharma-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/kite-pharma-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/kite-pharma-inc/stock-issued-shares-issued-shares-espps https://stock.noler.com/us/stock/kite-pharma-inc/stock-issued-shares-issued-value-espp https://stock.noler.com/us/stock/kite-pharma-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/kite-pharma-inc/stock-issued-value-of-shares-issued-for-acquisitions https://stock.noler.com/us/stock/kite-pharma-inc/stock-issued-value-of-shares-issued-for-stock-awards https://stock.noler.com/us/stock/kite-pharma-inc/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/kite-pharma-inc/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/kite-pharma-inc/stock-options-exercisable-number https://stock.noler.com/us/stock/kite-pharma-inc/stock-options-forfeitures-and-expirations-in-period https://stock.noler.com/us/stock/kite-pharma-inc/stock-options-forfeitures-and-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/kite-pharma-inc/stock-options-grants-in-period https://stock.noler.com/us/stock/kite-pharma-inc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/kite-pharma-inc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/kite-pharma-inc/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/kite-pharma-inc/stock-options-outstanding-number https://stock.noler.com/us/stock/kite-pharma-inc/stock-options-vested-and-expected-to-vest-outstanding-aggregate-intrinsic-value https://stock.noler.com/us/stock/kite-pharma-inc/stock-options-vested-and-expected-to-vest-outstanding-average-exercise-price https://stock.noler.com/us/stock/kite-pharma-inc/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/kite-pharma-inc/stock-options-vested-in-period-fair-value https://stock.noler.com/us/stock/kite-pharma-inc/stock-repurchase-program-number-of-shares-authorized-to-be-repurchased https://stock.noler.com/us/stock/kite-pharma-inc/straight-line-rent https://stock.noler.com/us/stock/kite-pharma-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/kite-pharma-inc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/kite-pharma-inc/tax-rate-reconciliation-disposition-of-assets https://stock.noler.com/us/stock/kite-pharma-inc/tax-rate-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/kite-pharma-inc/tax-rate-reconciliation-nondeductible-expense-meals-and-entertainment https://stock.noler.com/us/stock/kite-pharma-inc/tax-rate-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/kite-pharma-inc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/kite-pharma-inc/tax-rate-reconciliation-prior-year-income-taxes https://stock.noler.com/us/stock/kite-pharma-inc/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/kite-pharma-inc/tax-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/kite-pharma-inc/tax-reconciliation-other-adjustments https://stock.noler.com/us/stock/kite-pharma-inc/tax-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/kite-pharma-inc/taxes-and-licenses https://stock.noler.com/us/stock/kite-pharma-inc/technology-services-costs https://stock.noler.com/us/stock/kite-pharma-inc/tenant-improvements https://stock.noler.com/us/stock/kite-pharma-inc/tenant-reimbursements https://stock.noler.com/us/stock/kite-pharma-inc/total-assets https://stock.noler.com/us/stock/kite-pharma-inc/total-liabilities https://stock.noler.com/us/stock/kite-pharma-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/kite-pharma-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/kite-pharma-inc/utb-decrease-from-current-year-positions https://stock.noler.com/us/stock/kite-pharma-inc/utb-decrease-from-prior-year-positions https://stock.noler.com/us/stock/kite-pharma-inc/utb-income-tax-penalties-and-interest-accrued https://stock.noler.com/us/stock/kite-pharma-inc/utb-income-tax-penalties-and-interest-expense https://stock.noler.com/us/stock/kite-pharma-inc/utb-increase-from-current-year-positions https://stock.noler.com/us/stock/kite-pharma-inc/utb-increase-from-prior-year-positions https://stock.noler.com/us/stock/kite-pharma-inc/utb-interest-on-income-taxes-accrued https://stock.noler.com/us/stock/kite-pharma-inc/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/kite-pharma-inc/weighted-average-number-of-share-outstanding-basic-and-diluted https://stock.noler.com/us/stock/kite-pharma-inc/weighted-average-number-of-shares-common-stock-subject-to-repurchase-or-cancellation https://stock.noler.com/us/stock/kite-pharma-inc/workers-compensation-liability-current